Simplex Trading
PMCB icon

Simplex Trading’s PharmaCyte Biotech PMCB Stock Holding History

Simplex Trading’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.25K Hold
12,400
– – ﹤0.01% 7511
2025
Q4 		$8.98K Buy
+12,400
New +$11.2K ﹤0.01% 7059
2023
Q1 		– Sell
-74,200
Closed -$217K – 9875
2022
Q4 		$217K Sell
74,200
-700
-0.9% -$2K ﹤0.01% 4130
2022
Q3 		$179K Buy
74,900
+62,000
+481% +$157K ﹤0.01% 4762
2022
Q2 		$28K Buy
12,900
+1,300
+11% +$2.84K ﹤0.01% 7226
2022
Q1 		$26K Buy
11,600
+3,100
+36% +$6.89K ﹤0.01% 7942
2021
Q4 		$21K Buy
+8,500
New +$23.4K ﹤0.01% 8318

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Simplex Trading's PMCB Position: Q1 2026 in Review

Simplex Trading reduced its PharmaCyte Biotech (PMCB) stake by 23% in Q1 2026, selling an estimated $4.51K and leaving 19,940 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #7100.

Simplex Trading first reported a position in PMCB in Q2 2022 and has held it in 9 quarters since. The position peaked at $387K in Q1 2023. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Simplex Trading held 19,940 shares of PharmaCyte Biotech worth $13.3K as of Q1 2026.
  • Simplex Trading sold 5,894 PharmaCyte Biotech shares in Q1 2026, an estimated $4.51K.
  • PharmaCyte Biotech made up ﹤0.01% of Simplex Trading's portfolio in Q1 2026, its #7100 holding.
  • Simplex Trading first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 9 quarters since.
  • Simplex Trading's PharmaCyte Biotech position peaked at $387K in Q1 2023.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Simplex Trading's 13F filing for Q1 2026, filed 14 May 2026.